# Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)

> **NCT00286559** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University Hospital, Basel, Switzerland**

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** SonoVue
- **DRUG:** Optison

## Key facts

- **NCT ID:** NCT00286559
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** echo contrast agents no longer allowed in CAD patients.
- **Last updated:** 2015-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286559, "Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00286559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*